News | August 23, 2024
Nephro Care India reports 86.07% jump in PAT at Rs 4.41 crore during FY 23-24
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The partnership marks a significant milestone in integrating digital health education into medical curricula
He recently served as Senior Vice President of the API business at Shilpa Pharma Life Sciences for over 3 years
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Morepen Labs successfully raised Rs. 200 Crore through QIP
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Subscribe To Our Newsletter & Stay Updated
